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Background-—Plasma adiponectin levels have previously been inversely associated with carotid intima-media thickness (IMT), a
marker of subclinical atherosclerosis. In this study, we used a sex-stratiﬁed Mendelian randomization approach to investigate
whether adiponectin has a causal protective inﬂuence on IMT.
Methods and Results-—Baselineplasmaadiponectin concentrationwas tested for associationwithbaseline IMT, IMTprogressionover
30 months, and occurrence of cardiovascular events within 3 years in 3430 participants (women, n=1777; men, n=1653) with high
cardiovascular risk but no prevalent disease. Plasma adiponectin levels were inversely associated with baseline mean bifurcation IMT
after adjustment for established risk factors (b=0.018, P<0.001) in men but not in women (b=0.006, P=0.185; P for
interaction=0.061). Adiponectin levels were inversely associated with progression of mean common carotid IMT in men (b=0.0022,
P=0.047), whereas no association was seen in women (0.0007, P=0.475; P for interaction=0.018). Moreover, we observed that
adiponectin levels were inversely associated with coronary events in women (hazard ratio 0.57, 95% CI 0.37 to 0.87) but not in men
(hazard ratio0.82,95%CI0.54to1.25).Agenescoreofadiponectin-raisingalleles in6 loci, reportedrecently ina largemulti-ethnicmeta-
analysis, was inversely associated with baseline mean bifurcation IMT in men (b=0.0008, P=0.004) but not in women (b=0.0003,
P=0.522; P for interaction=0.007).
Conclusions-—This report provides some evidence for adiponectin protecting against atherosclerosis, with effects being conﬁned to
men; however, compared with established cardiovascular risk factors, the effect of plasma adiponectin was modest. Further
investigation involving mechanistic studies is warranted. ( J Am Heart Assoc. 2015;4:e001853 doi: 10.1161/JAHA.115.001853)
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A diponectin, a hormone with paracrine and endocrineeffects, is secreted from adipose tissue and circulates in
large amounts (3 to 30 mg/L) in plasma. In experimental
studies, it enhanced insulin sensitivity and exerted athero-
protective effects.1 Adiponectin effects are mediated by 3
receptors, adiponectin receptor 1, adiponectin receptor 2, and
T-cadherin, of which the ﬁrst 2 have intracellular domains2,3
and diverse abilities to regulate downstream inﬂammatory
cytokine responses.4
Low adiponectin levels are associated with obesity and
related cardiovascular risk factors (type 2 diabetes mellitus
[T2D],1 endothelial dysfunction,1 and dyslipidemia5). Low
adiponectin is also inconsistently6–9 associated with
increased risk of myocardial infarction, whereas high
adiponectin is associated with increased mortality in
populations with high cardiovascular risk.10–12 Moreover,
adiponectin is inversely associated with carotid intima-media
thickness (IMT), a marker of cardiovascular disease (CVD)
risk,13–16 independent of established risk factors. Evidence
suggests that IMT may be used as a surrogate marker for
atherosclerotic processes16,17 and future cardiovascular
events.18–20
It has yet to be demonstrated whether adiponectin levels
have a direct (rather than an indirect) effect on CVD. In
addition, it is unclear whether the signiﬁcantly higher
adiponectin levels observed in women compared with men
contribute to the striking sex difference in CVD risk. By
combining extensive ultrasound measures of IMT with plasma
adiponectin levels and adiponectin-associated genetic variants
identiﬁed in a multiethnic genomewide meta-analysis
(n=45 891),21 we used a Mendelian randomization approach22
to explore whether adiponectin has a causal inﬂuence on
carotid IMT in men and women in a large (n=3430) European
cohort with high CVD risk.
Materials and Methods
The IMPROVE Cohort
IMPROVE has been described previously.23 Brieﬂy, persons
with at least 3 classic CVD risk factors who were free of
clinical CVD at enrollment were recruited. Blood samples were
drawn at baseline and stored appropriately. A structured
medical history was obtained, and standard clinical and
biochemical phenotyping was carried out. Plasma adiponectin
concentration was analyzed with a double-antibody radioim-
munoassay (Millipore). The total coefﬁcients of variation were
15.2% at low levels (2 to 4 lg/mL) and 8.8% at high levels (26
to 54 lg/mL). T2D was deﬁned as a diagnosis of diabetes,
antidiabetic therapy, or fasting glucose ≥7 mmol/L at the
baseline examination. In addition, persons who started insulin
treatment before the age of 50 years were excluded. The
Framingham risk score was calculated for all participants.24 A
total of 3711 participants were recruited from 7 centers in
Finland, Sweden, the Netherlands, France, and Italy between
2002 and 2004.
Carotid Ultrasound Examination
The carotid ultrasound protocol and precision of the ultra-
sonographic measurements have been reported previously.23
The far walls of the left and right common carotid artery (CC)
and carotid bifurcation (Bif) were visualized in anterior, lateral,
and posterior projections and recorded on VHS videotapes.
IMT measurements were performed in a centralized laboratory
(Department of Pharmacological Sciences, University of Milan,
Italy). A dedicated software (M0Ath; Metris, SRL) that allowed
semiautomatic edge of the echogenic lines of the intima-
media complex was used. The entire lengths of the far walls of
the CCs and the Bifs were measured in at least 3 different
frames. The mean IMT (IMTmean) of each segment was
calculated (based on 6 measurements for each segment), and
the maximum IMT (IMTmax) for each segment was identiﬁed.
Measurements were taken at baseline and 30 months.
Progression at 30 months, expressed in mm/year,
was calculated by linear regression of IMT changes over
time. All scans for each patient were assigned to a single
reader after coding and were read blindly. As reported
previously,23 the intrasonographer intraclass correlation coef-
ﬁcents were 0.95 and 0.92 for CC-IMTmean and Bif-IMTmean,
respectively. The intersonographer intraclass correlation
coefﬁcents for the same carotid segments were 0.89 and
0.95, respectively.
Cardiovascular Events and Follow-up
Occurrence of cardiovascular end points (myocardial infarc-
tion, angioplasty, diagnosis of angina pectoris, angioplasty,
coronary artery bypass grafting and/or sudden cardiac death,
ischemic stroke, transient ischemic attack, peripheral revas-
cularization, and/or diagnosis of intermittent claudication)
was monitored after 30 months. Diagnoses of incident angina
pectoris, myocardial infarction, and ischemic stroke in the
course of the study were based on European Society of
Cardiology guidelines.1,2 Surgery or endovascular procedures
on the carotid arteries were not included as study end points
because they might be related to the baseline ultrasound
examination. All events were validated by local specialists
using medical records and death certiﬁcates and were
adjudicated subsequently by a designated specialist who
was blinded to the clinical history and IMT data. Coronary
events were deﬁned as myocardial infarction, sudden cardiac
death, angina pectoris, percutaneous coronary angioplasty, or
coronary artery bypass grafting.
DOI: 10.1161/JAHA.115.001853 Journal of the American Heart Association 2
Adiponectin and Carotid Intima-Media Thickness Persson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at U
N
IV
 LIBRA
RY
 on A
ugust 22, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Ethics Committee Approval
All participants provided written informed consent. The study
was approved by local ethics committees at the participating
institutions.
Single-Nucleotide Polymorphism Selection and
Genotyping
Adiponectin-associated single-nucleotide polymorphisms
(SNPs) from a large recent report by Dastani et al21 were
considered for inclusion in an allelic score. SNPs and proxies
used in the allelic score are presented in Table 1. SNPs
associated with T2D, diabetes-related traits, lipid traits, and
SNPs in the IRS1 locus25 were excluded to avoid analyzing
pleiotropic effects, leaving rs2791553, rs3001032, rs925735,
rs12051272, rs1597466, rs6810075, rs998584, and
rs592423 to be included in the allelic score (SNPs marked
with an asterisk in Table 1).
DNA was available for all participants. High-throughput
genotyping was performed using the Illumina 200K Car-
dioMetabo chip (SNP Technology Platform, Uppsala Univer-
sity, Sweden), and standard quality control procedures were
applied: SNPs were excluded for failing Hardy-Weinberg
equilibrium (P<19106) or call rate (95%) tests. Participants
were excluded because of low call rate (<95%), ambiguous
sex, cryptic relatedness, or non-European descent. Multidi-
mensional scaling components were calculated using
PLINK,26 and components 1 to 3 were included as
covariates in genetic analyses to control for population
structure. SNPs not present on the CardioMetabo chip were
genotyped using TaqMan SNP genotyping assays (Applied
Biosystems), and consistent quality control parameters were
applied.
After quality control, 3430 subjects with genetic informa-
tion, adiponectin levels, and IMT measures were included
(women, n=1777; men, n=1653; age range 54 to 79 years).27
Cohort characteristics are described in Table 2.
Statistical Methods
Differences in plasma adiponectin across centers were
analyzed by Kruskal–Wallis nonparametric 1-way analysis of
variance, and the Jonckheere–Terpstra test for ordered
alternatives was used to assess trends by latitude.
Associations among adiponectin levels, population struc-
ture (multidimensional scaling components [MDS] 1 to 3),
and established CVD risk factors were investigated by
calculation of Spearman rank correlation coefﬁcients. Fol-
lowing this, skewed variables were natural log-transformed
for normalization prior to further statistical analysis. Analysis
Table 1. SNPs and Proxies Included in the Allelic Score
CHR
Dastani et al21 IMPROVE
Lead
Minor/Major
Alleles MAF
b of Minor
Allele
Association With T2D, T2D-Related
Traits, or Lipids* Proxy
LD With Lead SNP
r2 (D0)
Minor/Major
Alleles MAF
1 rs2791553* A/G 0.40 0.02 No rs2494195 1 (1) T/C 0.38
1 rs3001032* C/T 0.30 0.02 No rs4846567 0.96 (1) T/G 0.27
2 rs925735* C/G 0.36 0.02 No rs2673141 1 (1) G/A 0.37
3 rs1108842 A/C 0.49 0.03 WHR A/C 0.48
3 rs12051272* T/G 0.03 0.26 No T/G 0.03
3 rs1597466* T/G 0.10 0.03 No rs4301033 0.90 (1) A/G 0.09
3 rs6810075* C/T 0.40 0.06 No rs1648707 0.90 (0.97) C/A 0.41
6 rs998584* A/C 0.50 0.03 No rs1358980 0.84 (0.93) T/C 0.48
6 rs592423* A/C 0.46 0.02 No A/C 0.47
8 rs2980879 A/T 0.31 0.03 HDL-C, LDL-C, TG, and total chol. rs2954030 0.80 (1) T/C 0.39
12 rs601339 G/A 0.19 0.03 HDL-C rs2454722 1 (1) G/A 0.19
12 rs7133378 A/G 0.30 0.02 HDL-C=c, TG A/G 0.32
16 rs2925979 T/C 0.30 0.04 HDL-C, TG T/C 0.32
19 rs731839 G/A 0.35 0.35 HDL-C, TG G/A 0.35
19 rs4805885 T/C 0.39 0.03 HDL-C rs8182584 0.86 (1) T/G 0.40
chol. indicates cholesterol; CHR, chromosome; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; LDL-C, low-density lipoprotein cholesterol; MAF, minor allele
frequency; major allele, noneffect allele; minor allele, effect allele; SNP, single-nucleotide polymorphism; TG, triglycerides; WHR, waist–hip ratio.
*Used in the allelic gene score.
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of factors associated with plasma adiponectin was per-
formed by multiple linear regression analysis (IBM SPSS
Statistics 19.0).
Linear regression analysis was conducted to assess
associations between adiponectin levels and IMT variables.
Analyses were stratiﬁed for sex because there were signiﬁ-
cant differences in adiponectin levels between men and
women. Adjustments were made for age (basic model) or for
age, body mass index, T2D, systolic blood pressure, current
smoking, triglycerides, high-density lipoprotein cholesterol,
and C-reactive protein (full model). Inclusion of waist–hip ratio
in the full model instead of body mass index made little or no
difference for the ﬁndings. Similarly, replacing current smok-
ing with quintiles of pack-years had negligible effects on the
Table 2. Baseline Characteristics and Measurements of Carotid IMT in IMPROVE and Replication Cohorts
Women Men
n 1777 1653
Age, y 64.6 (59.9 to 67.3) 64.5 (59.5 to 67.1)
SBP, mm Hg 140 (130 to 152) 141 (130 to 154)
DBP, mm Hg 80 (75 to 88) 83 (77 to 90)
Body mass index, kg/m2 26.5 (23.6 to 29.7) 27.1 (24.9 to 29.3)
LDL-C, mmol/L 3.6 (2.9 to 4.4) 3.4 (2.7 to 4)
HDL-C, mmol/L 1.3 (1.1 to 1.6) 1.1 (0.93 to 1.3)
Triglycerides, mmol/L 1.26 (0.91 to 1.79) 1.38 (0.97 to 2.03)
Creatinine, mmol/L 70 (63 to 79) 89 (80 to 99)
C-reactive protein, mg/L 2.10 (0.92 to 3.95) 1.63 (0.67 to 3.23)
Fasting glucose, mmol/L 5.3 (4.8 to 6.0) 5.7 (5.2 to 6.6)
Adiponectin, lg/mL 14.1 (8.7 to 22.0) 8.2 (5.0 to 12.2)
Ultrasonographic variables
Baseline
CC-IMTmean, mm 0.70 (0.64 to 0.77) 0.74 (0.66 to 0.83)
CC-IMTmax, mm 1.03 (0.94 to 1.19) 1.13 (0.98 to 1.44)
Bif-IMTmean, mm 1.00 (0.81 to 1.25) 1.12 (0.91 to 1.44)
Bif-IMTmax, mm 1.57 (1.26 to 2.13) 1.77 (1.39 to 2.41)
Progression
CC-IMTmean, mm 0.006 (0.006 to 0.020) 0.008 (0.006 to 0.024)
CC-IMTmax, mm 0.004 (0.019 to 0.039) 0.011 (0.023 to 0.050)
Bif-IMTmean, mm 0.027 (0.004 to 0.066) 0.031 (0.006 to 0.073)
Bif-IMTmax, mm 0.036 (0.012 to 0.112) 0.037 (0.026 to 0.114)
Smoking habits
Never 31.2 (515) 63.9 (1136)
Former 52.3 (864) 22.7 (403)
Current 16.6 (274) 13.4 (238)
Type 2 diabetes mellitus* 22.0 (386) 32.0 (514)
Drugs at inclusion
Antiplatelet therapy 14.6 (259) 18.7 (309)
Oral antidiabetic drugs 13.7 (241) 21.7 (352)
Insulin 3.1 (55) 4.5 (74)
Lipid-lowering drugs 51.1 (896) 47.7 (774)
Antihypertensive drugs 59.1 (1051) 54.3 (898)
Values are median (interquartile range) or percentage (number). Bif indicates bifurcation of the carotid artery; CC, common carotid artery; DBP, diastolic blood pressure; HDL-C, high-
density lipoprotein cholesterol; IMT, intima-media thickness; IMTmax, highest of all maximal IMT values obtained from left and right measurements; IMTmean, average of mean IMT values
obtained from left and right measurements; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
*Deﬁned as a diagnosis of diabetes, antidiabetic therapy, or fasting glucose ≥7 mmol/L at the baseline examination.
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results. Tests for sex–adiponectin interaction were performed
for the entire cohort.
Cox proportional hazards analysis adjusting for baseline
characteristics in basic and full models, as speciﬁed, was
used to determine association of plasma adiponectin with
cardiovascular events and coronary events only. The propor-
tionality assumption was tested with time-dependent vari-
ables.
For the Mendelian randomization, an unweighted allelic
score was constructed by calculating the sum of alleles
associated with increased plasma adiponectin divided by the
maximum number of possible adiponectin-raising alleles. To
account for possible population structure, MDS 1 to 3 were
included as covariates in regression models. MDS (compara-
ble with principal component analysis) was performed using
largely uncorrelated CardioMetabochip SNPs obtained by
applying a ﬁlter of pairwise correlations of r2<0.5 within a 50-
SNP window that iteratively shifted 5 SNPs along the
sequence. The ﬁrst component corresponded well with the
latitude of the recruitment center, whereas the second
approximated longitude. Analysis of allelic score associations
Figure 1. Lower plasma adiponectin concentrations were observed in northern recruitment centers.
Table 3. Effect Size Estimates for Variables Associated With
Plasma Adiponectin in Multivariable Models
Women Men
Partial g2 P Value Partial g2 P Value
Age 0.007 <0.001 0.002 0.089
SBP 0.000 0.881 0.000 0.890
Body mass index 0.002 0.075 0.005 0.004
HDL-C 0.036 <0.001 0.018 <0.001
Triglycerides 0.023 <0.001 0.010 <0.001
Type 2 diabetes mellitus 0.017 <0.001 0.013 <0.001
Current smoking 0.000 0.502 0.000 0.671
C-reactive protein 0.003 0.025 0.001 0.317
MDS1 0.165 <0.001 0.080 <0.001
MDS2 0.011 <0.001 0.010 <0.001
MDS3 0.003 0.027 0.002 0.047
g2 for model 0.320 <0.001 0.192 <0.001
HDL-C indicates high-density lipoprotein cholesterol; MDS, multidimensional scaling
component; SBP, systolic blood pressure.
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with IMT were performed with basic (adjusting for population
structure and age) and full (adjusting for population structure,
age, body mass index, systolic blood pressure, high-density
lipoprotein cholesterol, triglycerides, C-reactive protein,
current smoking, T2D) linear regression models. Tests of
sex–allelic score interactions were performed for the entire
cohort. Multiple testing correction was not applied to the
analysis of IMT variables because the phenotypes are closely
interrelated.23
Results
Baseline characteristics and ultrasonographic variables are
presented in Table 2. Men and women differed for most
variables including adiponectin levels, which were higher in
women (median 14.1 [interquartile range 8.7 to 22.0] versus
8.2 [interquartile range, 5.0 to 12.2] lg/mL). Adiponectin
levels also differed across centers, with signiﬁcantly lower
adiponectin levels in the north observed in both men and
women (Figure 1). Of note, MDS component 1 (to a large
degree reﬂecting south-to-north population structure) was
associated with adiponectin and accounted for 16.5% and
8.0% of adiponectin variation in women and men, respectively
(Table 3).
Sex-speciﬁc associations between adiponectin and estab-
lished cardiovascular risk factors are shown in Table 4.
Adiponectin levels were inversely associated with blood
pressure, body mass index, triglycerides, creatinine, C-reactive
protein, and T2D and were positively associated with age and
high-density lipoprotein cholesterol.
Adiponectin Levels and Baseline IMT
In men, adiponectin levels were inversely associated with
CC-IMTmean and Bif-IMTmean and Bif-IMTmax, but only the
associations with Bif-IMTmean remained signiﬁcant after
adjustment for established CVD risk factors (Table 5). In
women, adiponectin was inversely associated with the means
of both CC-IMT and Bif-IMT in the basic model; however,
Table 4. Correlations Between Plasma Adiponectin
Concentration and Established Cardiovascular Risk Markers
Men (n=1653) Women (n=1777)
r P Value r P Value
Age 0.081 0.001 0.065 0.006
SBP 0.083 0.001 0.152 <0.001
DBP 0.104 <0.001 0.135 <0.001
Body mass index 0.188 <0.001 0.311 <0.001
LDL-C 0.12 <0.001 0.194 <0.001
HDL-C 0.206 <0.001 0.323 <0.001
Triglycerides 0.171 <0.001 0.285 <0.001
Creatinine 0.084 0.001 0.095 <0.001
C-reactive protein 0.062 0.012 0.159 <0.001
Fasting glucose 0.255 <0.001 0.36 <0.001
Type 2 diabetes mellitus 0.192 <0.001 0.257 <0.001
Current smoking 0.036 0.142 0.055 0.021
MDS1 0.246 <0.001 0.324 <0.001
MDS2 0.114 <0.001 0.005 0.846
MDS3 0.038 0.120 0.078 0.001
Values are Spearman rank correlation coefﬁcients. DBP indicates diastolic blood
pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; MDS, multidimensional scaling component; SBP, systolic blood pressure.
Table 5. Associations Between Plasma Adiponectin and Baseline IMT
Model
Men (n=1653) Women (n=1777)
P Value Int*b 95% CI P Value b 95% CI P Value
CC-IMTmean Basic 0.007 0.012 to 0.002 0.006 0.005 0.009 to 0.002 0.007 0.737
Full 0.003 0.008 to 0.002 0.233 0.001 0.005 to 0.003 0.644 0.261
CC-IMTmax Basic 0.007 0.015 to 0.001 0.080 0.004 0.010 to 0.003 0.228 0.661
Full 0.003 0.011 to 0.005 0.471 0.002 0.005 to 0.009 0.613 0.367
Bif-IMTmean Basic 0.020 0.029 to 0.011 <0.001 0.013 0.021 to 0.005 0.002 0.240
Full 0.018 0.027 to 0.009 <0.001 0.006 0.015 to 0.003 0.185 0.061
Bif-IMTmax Basic 0.023 0.033 to 0.012 <0.001 0.011 0.021 to 0.001 0.029 0.121
Full 0.019 0.030 to 0.008 0.001 0.006 0.017 to 0.004 0.247 0.037
Basic model was adjusted for age. Full model was adjusted for age, body mass index, type 2 diabetes mellitus, systolic blood pressure, current smoking, triglycerides, high-density
lipoprotein cholesterol, and C-reactive protein. Bif indicates bifurcation of the carotid artery; CC, common carotid artery; IMT, intima-media thickness; IMTmax, highest of all maximal IMT
values obtained from left and right measurements; IMTmean, average of mean IMT values obtained from left and right measurements; Int, interaction.
*Sex–adiponectin interaction.
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further adjustment attenuated the association. Sex interacted
with adiponectin to signiﬁcantly inﬂuence Bif-IMTmax in the
fully adjusted model but not in the basic model (Table 5).
Adiponectin Levels and Progression of IMT
In men, adiponectin levels were inversely associated with
progression of CC-IMTmean and CC-IMTmax, despite adjust-
ment for established cardiovascular risk factors (Table 6),
whereas the association with Bif-IMTmean was lost when
adjusting for the full model. In women, an inverse association
with progression of Bif-IMTmax was observed in the basic
model only. Sex interacted signiﬁcantly with adiponectin to
inﬂuence progression of CC-IMTmean and CC-IMTmax but not
Bif-IMTmean or Bif-IMTmax.
Adiponectin Levels and Cardiovascular Events
During follow-up, there were 74 and 117 cardiovascular
events (45 and 75 coronary events) among women and men,
respectively. In univariate analysis, age, body mass index,
high-density lipoprotein cholesterol, triglycerides, creatinine,
C-reactive protein, and T2D were associated with cardiovas-
cular events in women, whereas age, systolic blood pressure,
Table 6. Associations Between Plasma Adiponectin and Progression of IMT
Model
Men (n=1653) Women (n=1777)
P Value Int*b 95% CI P Value b 95% CI P Value
CC-IMTmean Basic 0.003 0.005 to 0.0007 0.008 0.0002 0.002 to 0.0019 0.867 0.034
Full 0.002 0.004 to 3.09105 0.047 0.0007 0.001 to 0.0025 0.475 0.018
CC-IMTmax Basic 0.007 0.014 to 0.0007 0.031 0.0029 0.003 to 0.0089 0.347 0.020
Full 0.007 0.014 to 0.0001 0.045 0.0031 0.004 to 0.0097 0.354 0.024
Bif-IMTmean Basic 0.007 0.012 to 0.0013 0.015 0.0040 0.008 to 0.0011 0.135 0.309
Full 0.004 0.010 to 0.0019 0.186 0.0020 0.008 to 0.0028 0.371 0.229
Bif-IMTmax Basic 0.006 0.017 to 0.0061 0.349 0.0120 0.022 to 0.0010 0.026 0.523
Full 0.002 0.014 to 0.0104 0.789 0.0110 0.022 to 0.0005 0.061 0.582
Basic model was adjusted for age. Full model was adjusted for age, body mass index, type 2 diabetes mellitus, systolic blood pressure, current smoking, triglycerides, high-density
lipoprotein cholesterol, and C-reactive protein. Bif indicates bifurcation of the carotid artery; CC, common carotid artery; IMT, intima-media thickness; IMTmax, highest of all maximal IMT
values obtained from left and right measurements; IMTmean, average of mean IMT values obtained from left and right measurements; Int, interaction.
*Sex–adiponectin interaction.
Table 7. Univariable Associations With Cardiovascular Events in Women and Men
Women Men
HR* 95% CI P Value HR* 95% CI P Value
Age 1.24 1.02 to 1.52 0.034 1.32 1.12 to 1.56 0.001
SBP 1.11 0.89 to 1.39 0.346 1.26 1.06 to 1.49 0.007
DBP 0.92 0.73 to 1.17 0.504 1.10 0.92 to 1.31 0.286
Body mass index 1.23 1.03 to 1.48 0.025 1.08 0.87 to 1.33 0.483
LDL-C 0.99 0.79 to 1.24 0.922 1.11 0.91 to 1.35 0.312
HDL-C 0.76 0.59 to 0.97 0.031 0.88 0.70 to 1.10 0.263
Triglycerides 1.30 0.98 to 1.72 0.065 1.07 0.98 to 1.16 0.120
Creatinine 1.24 0.98 to 1.57 0.076 1.21 1.02 to 1.44 0.028
C-reactive protein 1.18 1.02 to 1.35 0.022 1.17 1.02 to 1.35 0.024
Fasting glucose 1.21 0.99 to 1.48 0.065 1.02 0.87 to 1.20 0.769
Current smoking 1.32 0.73 to 2.41 0.361 1.64 1.07 to 2.50 0.023
Type 2 diabetes mellitus 2.14 1.33 to 3.45 0.002 1.16 0.79 to 1.71 0.450
DBP indicates diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
*HR for 1 SD increase is reported for continuous variables except age, for which HR per 5-year increase is reported.
DOI: 10.1161/JAHA.115.001853 Journal of the American Heart Association 7
Adiponectin and Carotid Intima-Media Thickness Persson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at U
N
IV
 LIBRA
RY
 on A
ugust 22, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
creatinine, and current smoking were associated with cardio-
vascular events in men (Table 7).
Adiponectin levels were associated with coronary events in
women in the basic model (hazard ratio [HR] per 1 SD
increase of plasma adiponectin 0.48, 95% CI 0.32 to 0.72)
and in the full model (HR 0.57, 95% CI 0.37 to 0.87). In men,
no association was detected between adiponectin levels and
coronary events (HR 0.74 [95% CI 0.50 to 1.09] and 0.82
[95% CI 0.54 to 1.25], respectively). When considering all
cardiovascular events in women, an association with
adiponectin was observed in the basic model (HR 0.64, 95%
CI 0.49 to 0.85), but this was lost on further adjustment (HR
0.76, 95% CI 0.57 to 1.02). In men, no association was
observed between adiponectin and all cardiovascular events
(HR 0.76 [95% CI 0.56 to 1.03] and 0.81 [95% CI 0.58 to
1.13], respectively).
Mendelian Randomization Analysis
To assess causality (and avoid reverse causation), a Men-
delian randomization approach22 was used. If higher adipo-
nectin levels have a direct causal role in reducing IMT
measures, then genetic variants that increase adiponectin
levels throughout life would be expected to demonstrate an
association with lower IMT measures. Consequently, associ-
ations between an allelic score of adiponectin-increasing
SNPs21 and IMT measures were investigated.
The allelic score explained 1.7% and 1.2% of variation in
baseline plasma adiponectin levels in men and women,
respectively. The allelic score was inversely associated with
systolic blood pressure (men and women) and glucose
(women only) (Table 8). It is worth noting that women with
the least adiponectin-increasing alleles had higher levels of
adiponectin than the men with the highest allelic scores
(Table 9).
In men, the allelic score was inversely associated with
baseline Bif-IMTmean and Bif-IMTmax in the basic and full
models (Table 10; Figure 2). In women, no associations with
IMT were detected. There was a sex–allelic score interaction
for Bif-IMTmean and Bif-IMTmax (Table 10). No allelic score
associations were observed with IMT progression measures
(data not shown).
Allelic Score and Incident CVD Events
The allelic score was inversely associated with coronary
events in men (but not women) in the basic and full models
(Table 11). Men with the lowest allelic scores, 0 to 40, had
more incident coronary events than men with higher allelic
scores (Figure 3).
Table 8. Independent Allelic Score in Relation to Baseline Characteristics in Women and Men
Variable
Women Men
b 95% CI P Value b 95% CI P Value
Age 0.0001 0.0204 to 0.0206 0.993 0.0055 0.0258 to 0.0149 0.599
Body mass index 0.0076 0.0256 to 0.0103 0.404 0.0129 0.0270 to 0.0011 0.071
SBP 0.1256 0.1951 to 0.0561 <0.001 0.0752 0.1452 to 0.0053 0.035
LDL-C 0.0017 0.0023 to 0.0057 0.408 0.0031 0.0005 to 0.0067 0.095
Triglycerides 0.0010 0.0009 to 0.0029 0.296 0.0003 0.0019 to 0.0024 0.815
HDL-C 0.0003 0.0013 to 0.0007 0.542 0.0005 0.0015 to 0.0005 0.320
C-reactive protein 0.0023 0.0022 to 0.0068 0.309 0.0028 0.0020 to 0.0076 0.255
Fasting glucose 0.0012 0.0020 to 0.0004 0.004 0.0008 0.0017 to 0.0001 0.099
Type 2 diabetes mellitus 0.0031 0.9879 to 1.0059 0.497 0.0079 0.9839 to 1.0005 0.065
Linear regression analysis in for continuous variables and logistic regression analysis for type 2 diabetes mellitus. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; SBP, systolic blood pressure.
Table 9. Allelic Score in Relation to Plasma Adiponectin in Women and Men
Allelic Score 0 to 40 >40 to 50 >50 to 60 >60 to 70 >70 to 100
Women, lg/mL 12.7 (8.0 to 21.3) 13.2 (8.7 to 20.8) 13.9 (8.8 to 21.8) 14.7 (9.0 to 22.2) 17.9 (11.2 to 24.7)
Men, lg/mL 6.5 (3.9 to 11.0) 7.8 (4.8 to 11.9) 8.1 (4.9 to 12) 8.6 (5.7 to 12.8) 9.7 (5.9 to 14.5)
Values are median (interquartile range).
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Discussion
This study is the ﬁrst to address the issue of whether
adiponectin has direct effects on CVD, using molecular
genetics, plasma adiponectin measurements, and repeated
carotid IMT imaging in the longitudinal IMPROVE study.23
Furthermore, as this was the largest single study of
adiponectin in relation to IMT to date, we were able to
examine sex-speciﬁc effects of adiponectin on IMT in the CC
and the Bif of the carotid artery.
Whereas other studies have reported associations between
adiponectin and IMT,13–16 this report highlighted differences
in the effect of adiponectin along the carotid tree: Adiponectin
levels were associated with the Bif-IMT at baseline and with
progression of the CC. It should be noted that baseline
associations reﬂect lifetime (≥60 years) exposure to plasma
adiponectin levels and the allelic score, whereas progression
of CC-IMT reﬂects 30 months of exposure. These ﬁndings
may be relevant in light of differences between CC-IMT and
Bif-IMT; in general, CC-IMT is not a measure of atherosclerosis
but rather a thickening of the media in response to age and
high shear stress and is associated with hypertension and
prevalent stroke.28,29 Carotid atherosclerosis occurs predom-
inantly in the Bif19 in an area of low shear stress, and Bif-IMT
is associated primarily with coronary heart disease risk
factors and prevalent coronary heart disease.19,28
Of note, it is possible that our ﬁnding that levels of
adiponectin showed a north–south trend (lower in the north),
even after adjustment for established cardiovascular risk
factors, might contribute to the previously demonstrated
opposite north–south gradient in IMT (larger in the north)23;
however, further work is required to conﬁrm this ﬁnding.
To assess causality, we used Mendelian randomization to
demonstrate causal effects of adiponectin on the carotid tree,
using an allelic score of adiponectin-increasing SNPs deter-
mined in a large multiethnic analysis of 45 891 persons.21 To
minimize pleiotropic effects, SNPs signiﬁcantly associated
with T2D, diabetes-related traits, and lipid traits were
excluded from the allelic score. Despite this, associations
with systolic blood pressure (in women and to some extent in
men) and fasting glucose (in women only) were observed. In
men, we could show that the allelic score was associated with
Bif-IMT and could provide support for a protective role of
adiponectin in early atherosclerosis, as assessed by IMT;
however, it should be noted that the effect of adiponectin
(plasma levels and score) was modest and limited to the Bif and
thus cannot be generalized to the rest of the carotid artery.
Table 10. Association of the Allelic Score With Baseline IMT
Model
Men (n=1653) Women (n=1777)
P Value Int*b 95% CI P Value b 95% CI P Value
CC-IMTmean Basic 0.0002 0.0005 to 0.0001 0.125 0.0001 0.0001 to 0.0003 0.425 0.158
Full 0.0002 0.0005 to 0.0001 0.120 0.0001 0.0001 to 0.0004 0.270 0.114
CC-IMTmax Basic 0.0002 0.0007 to 0.0002 0.312 0.0002 0.0002 to 0.0005 0.432 0.321
Full 0.0003 0.0007 to 0.0002 0.299 0.0002 0.0002 to 0.0006 0.278 0.255
Bif-IMTmean Basic 0.0008 0.0013 to 0.0003 0.003 0.0001 0.0004 to 0.0006 0.666 0.009
Full 0.0008 0.0013 to 0.0003 0.004 0.0002 0.0003 to 0.0007 0.522 0.007
Bif-IMTmax Basic 0.0009 0.0016 to 0.0003 0.004 0.0001 0.0005 to 0.0007 0.688 0.011
Full 0.0009 0.0015 to 0.0003 0.006 0.0002 0.0004 to 0.0008 0.556 0.011
Basic model was adjusted for age and population structure. Full model was adjusted for age, population structure, body mass index, type 2 diabetes mellitus, systolic blood pressure, current
smoking, triglycerides, high-density lipoprotein cholesterol, and C-reactive protein. Bif indicates bifurcation of the carotid artery; CC, common carotid artery; IMT, intima-media thickness;
IMTmax, highest of all the maximal IMT values obtained from left and right measurements; IMTmean, average of mean IMT values obtained from left and right measurements; Int, interaction.
*Sex–allelic score interaction.
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Figure 2. The allelic score in relation to log Bif-IMTmean (blue
bars) and plasma adiponectin (green line) in men. Bif-IMT indicates
bifurcation intima-media thickness.
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It is worth noting that in this cohort with high CVD risk, the
majority of participants were on lipid-lowering and/or antihy-
pertensive medication. Analysis of untreated participants only
is underpowered (n=372 men, n=368 women) but demon-
strates effect sizes comparable to the whole cohort (data not
shown). Similarly, stratiﬁcation (rather than adjustment) for
T2D status might be preferable but would severely limit power.
Differences in effect of either adiponectin or allelic score on all
studied phenotypes were minimal between the whole popula-
tion and participants with or without T2D (data not shown).
The Framingham risk score24 suggests that certain CVD
risk factors are more important than others. Calculation of the
Framingham risk score indicates that 1358 men and 632
women in this study were classiﬁed as being at high risk of
CVD (Framingham risk score >0.20). Considering only this
subset of the population, effect sizes were generally stronger
than in the whole population, with the same phenotypes
demonstrating signiﬁcance for baseline IMT (but not progres-
sion) in analysis of either adiponectin (data not shown) or
allelic score (Table 12).
In addition, we demonstrated that there are sex-speciﬁc
effects: Adiponectin levels and allelic scores were associated
with IMT measures of the carotid Bif in men but not in women
(even after adjustment for established cardiovascular risk
factors), and adiponectin levels were associated with coronary
events in women but not in men. That associations with IMT
are not consistent with those for coronary events is not a
surprise. As noted, baseline IMT measures of the carotid Bif
can be considered a surrogate marker for the development of
atherosclerosis from birth until enrollment in the study (over a
time span of 65 years). In contrast, the cardiovascular
events are acute incidents due to plaque rupture and
atherosclerosis. Consequently, the 2 parameters studied
reﬂect different components of CVD.
The sex-speciﬁc differences in effect of adiponectin on
CVD may be due to the differences in levels of adiponectin
between men and women. Because the effects of adiponectin-
raising alleles in women on IMT measures were negligible, it
could be hypothesized that women with low adiponectin still
have enough adiponectin to prevent or slow atherosclerosis
development. In contrast, men with few adiponectin-raising
alleles (allelic score 0 to 40) had very low adiponectin levels
(6.5 lg/mL, interquartile range 3.9 to 11.0 lg/mL), which
may be permissive of the atherosclerosis process compared
with men with higher allelic scores (allelic score >70 to 100)
and higher adiponectin levels (9.7 lg/mL, interquartile range
5.9 to 14.5 lg/mL).
Strengths and Limitations
A limitation of this study is the lack of information regard-
ing hormone replacement therapy. Accordingly, complete
assessment of the effect of female sex hormones on
adiponectin is not possible. We cannot rule out that this
might contribute to the sex differences reported. In addition,
our results are primarily informative for participants with high
cardiovascular risk and may not pertain to the general
population. Furthermore, during the review process, a number
of reports were published demonstrating associations
Table 11. Associations Between the Allelic Score and Coronary or Cardiovascular Events
Model
Men (n=1653) Women (n=1777)
HR* 95% CI P Value HR* 95% CI P Value
Coronary events Basic 0.73 0.58 to 0.93 0.012 0.96 0.71 to 1.31 0.798
Full 0.76 0.6 to 0.96 0.023 0.95 0.7 to 1.29 0.747
Cardiovascular events Basic 0.82 0.68 to 1.00 0.045 0.93 0.73 to 1.19 0.561
Full 0.83 0.68 to 1.01 0.059 0.93 0.73 to 1.18 0.562
Basic model was adjusted for age and population structure. Full model was adjusted for age, population structure, body mass index, type 2 diabetes mellitus, systolic blood pressure,
current smoking, triglycerides, high-density lipoprotein cholesterol, and C-reactive protein. HR indicates hazard ratio.
*HR for 1 SD increase in allelic score.
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Figure 3. Kaplan–Meier plot of freedom from coronary events
in men classiﬁed according to the allelic score.
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between T2D-relevant traits and the loci that previously did
not show evidence of pleiotropy, hence we cannot exclude
pleiotropic effects of the allelic score. The lack of association
between the plasma adiponectin and coronary events in men
might be due to lack of statistical power. Despite these
limitations, the IMPROVE study has comprehensive measure-
ments of IMT at baseline and after 30 months in addition to
adiponectin levels and dense genotyping. Furthermore, infor-
mation on cardiovascular events is complete for 94.5% of
participants over 3 years, limiting any follow-up bias.
Although consistent, the effects of plasma adiponectin levels
and allelic scores on Bif-IMT were much smaller than those
provided by established CVD risk factors. In summary, this
study ﬁlls a gap in the ﬁeld and adds some support for a
causal relationship between adiponectin and IMT.
Conclusions
This report provides some evidence of adiponectin protecting
against atherosclerosis; however, this effect is limited to a
speciﬁc part of the carotid artery (the Bif) and only to men,
and the magnitude is modest. Mechanistic studies are
warranted to clarify the exact nature of the effect.
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Table 12. Association of the Allelic Score With Baseline IMT in Subjects With Framingham Risk Score >0.20
Model
Men (n=1653) Women (n=1777)
P Value Int*b 95% CI P Value b 95% CI P Value
CC-IMTmean Basic 0.0001 0.0005 to 0.0002 0.478 0.0003 0.0002 to 0.0007 0.250 0.268
Full 0.0001 0.0005 to 0.0002 0.489 0.0003 0.0002 to 0.0007 0.249 0.221
CC-IMTmax Basic 0.0000 0.0006 to 0.0005 0.869 0.0004 0.0003 to 0.0011 0.283 0.435
Full 0.0000 0.0006 to 0.0005 0.875 0.0004 0.0004 to 0.0011 0.344 0.419
Bif-IMTmean Basic 0.0007 0.0013 to 0.0001 0.023 0.0004 0.0005 to 0.0013 0.388 0.017
Full 0.0007 0.0013 to 0.0001 0.020 0.0003 0.0006 to 0.0012 0.520 0.020
Bif-IMTmax Basic 0.0008 0.0015 to 0.0001 0.024 0.0005 0.0006 to 0.0015 0.398 0.019
Full 0.0008 0.0015 to 0.0001 0.026 0.0004 0.0007 to 0.0015 0.472 0.024
Basic model was adjusted for age and population structure. Full model was adjusted for age, population structure, body mass index, type 2 diabetes mellitus, systolic blood pressure, current
smoking, triglycerides, high-density lipoprotein cholesterol, and C-reactive protein. Bif indicates bifurcation of the carotid artery; CC, common carotid artery; IMT, intima-media thickness;
IMTmax, highest of all the maximal IMT values obtained from left and right measurements; IMTmean, average of mean IMT values obtained from left and right measurements; Int, interaction.
*Sex–allelic score interaction.
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